Clinical trial NCT05353244: Effects of PrTMS on Performance
Official title: Effects of Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) on Human Performance and Sleep Quality
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Sleep Quality
Cognition Improvement
Keywords: PrTMS
EEG
Sleep
Cogniton
Lead sponsor: West Virginia University
Sponsor class: OTHER
First posted: 2022-04-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomly assigned to an active or sham intervention group. Each participant will complete 30 PrTMS or sham sessions. Through the course of the 6-week study, participants will be asked to wear a lab-provided sleep tracking ring (Oura).

Each participant, regardless of group, will complete daily and weekly surveys and assessments including a qEEG and cognitive assessments. At the intake, midpoint, and exit, a battery of surveys will be administered as well.
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to assess the ability of a form of non-invasive brain stimulation called personalized repetitive transcranial magnetic stimulation, or PrTMS, to enhance cognitive performance and sleep quality from baseline metrics.

Detailed description: Repetitive Transcranial Magnetic Stimulation (rTMS) is an FDA approved, non-invasive, non-pharmaceutical strategy for treating adults with major depression. This particular treatment strategy is also deemed safe and well-tolerated per the numerous clinical trials of over 300 patients. Additionally, the extant literature reports numerous occurrences of human performance enhancement in association with rTMS, such as better visual perception, motor learning, objective identification, attention, memory, as well as faster eye movements. However, recent advancements in rTMS yield promise for a more personalized protocol that is specific to individual needs and is based on quantitative electroencephalography (qEEG), enabling a correlation between qEEG and human behavior, though further investigation is necessary. Therefore, this study will examine personalized qEEG-guided rTMS (PrTMS) based upon each patient's pretreatment qEEG readings.

PrTMS uses neural alpha wave dynamics to target its TMS intervention via PeakLogic software with respect to location and frequency of TMS application. If PrTMS is effective, then researchers should be able to observe specific changes, e.g., more consistent fundamental frequency and increased alpha wave coherence across multiple brain sites, as PrTMS interventions progress. More importantly, alpha wave coherence is known to be associated with improved sleep behavior, cognition, and emotional reactivity. Thus, it is reasonable to hypothesize that changes in neural activity (as detected via qEEG) may result in several positive behavioral and perceptual (e.g., improved mood state/reduced anxiety) responses even for healthy populations.

The goal of PrTMS is to steadily nudge neural alpha wave responses towards a common fundamental frequency (10 to 12 Hz) across all brain regions. These frequencies vary over time, like all natural systems, with larger variations thought to be tied to behavioral symptomologies such as anxiety, PTSD, sleep disturbances and other conditions. Once this goal is achieved, neural activity across the brain is in coherence, which is assumed to be a natural and more efficient state for brain activity, with downstream effects such as the alleviation of symptoms relevant to brain-related disease/injury and/or heightened cognitive function.

Provided the well understood importance of adequate sleep and keen cognition for both the quality of daily living as well as longevity, efforts to thwart any potential disturbances to either offers promise for the betterment of the RNI's targeted populations, AMP2 (Athletics, Military, Patient, and general Population communities). Further, there are very intimate associations between sleep and cognition; put simply, the more one sleeps and the better quality of said sleep, the better one's cognitive skills will be the subsequent day. Indeed, previous research reported improved attentional focus, cognitive processing, and memory development with greater sleep durations. Contrarily, when one is deprived of sleep, one might expect to experience decreased physical performance capabilities (e.g., decreased force production), deleterious effects to glucose metabolism, poor appetite, diminished protein synthesis at the cellular level, as well as increased systemic inflammation. One intriguing strategy for improving sleep and cognition that is both noninvasive and non-pharmaceutical is Transcranial Magnetic Stimulation (TMS). Previous literature suggests that Transcranial Magnetic Stimulation was effective in enhancing both sleep and cognitive performance3. Further, Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS) demonstrated increased efficacy in TMS treatments through utilizing quantitative electroencephalography (qEEG) and fine tuning the treatment to the individual. Yet, research examining the integration of PrTMS with assessments of sleep and cognition is scarce. Therefore, the main objective of this proposed study is to investigate the use of PrTMS, utilizing qEEG weekly for individualization, and the effects on sleep, cognitive performance, and overall wellness in healthy subjects.

Eligibility criteria: Inclusion Criteria:

* Male or female between 18-42 years of age.

Exclusion Criteria:

* • Unable/unwilling to commit to participating in 1x per day treatments for 6 consecutive weeks

  * Outside of the age range of 18-42
  * Currently undergoing hormone therapy
  * History of blood clotting disorder
  * History of open skull traumatic brain injury
  * History of clinically significant seizure disorder
  * History of clinically significant manic episodes
  * Diagnosed with Diabetes Mellitus
  * Individuals with a clinically defined neurological disorder including, but not limited to:

    * Any condition likely to be associated with increased intracranial pressure
    * Space occupying brain lesion
    * History of cerebrovascular accident
    * Cerebral aneurysm
  * Has participated in any type of rTMS treatment within 3 months prior to the screening visit
  * Currently receiving antipsychotic or anticonvulsant medication treatment
  * Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed
  * Clinically significant medical illness, including any uncontrolled thyroid disorders, hepatic, cardiac, pulmonary and renal malfunctioning
  * History of psychosis
  * History of migraines
  * Current thoughts of suicidal ideation or self-harm
  * Substance use disorder within the past six months
  * Those pregnant or actively trying to become pregnant
  * Intake of one or a combination of the following drugs forms a 'Strong Potential Hazard' for application of rTMS due to their significant seizure threshold lowering potential:

    * Imipramine
    * Amitriptyline
    * Doxepine
    * Nortriptyline
    * Maprotiline
    * Chlorpromazine
    * Clozapine
    * Foscarnet
    * Ganciclovir
    * Ritonavir
    * Amphetamines
    * Cocaine (MDMA, ecstasy)
    * Phencyclidine (PCP, angel's dust)
    * Ketamine
    * Gamma-hydroxybutyrate (GHB)
    * Alcohol
    * Theophylline
    * Note: Being on one of these medications or substances would not automatically exclude a participant from study participation. The risk is dependent on the patient's past medical history, drug dose, speed of dose increase (or decrease), history of recent medication changes or duration of treatment, and combination with other CNS active drugs. Considering all the variables and keeping participant safety in mind, if a potential participant is on any of the above medication, the participant will be carefully evaluated and a justification for the decision to include them in the study will be documented by the medically responsible physician.
  * Recent withdrawal from one of the following drugs forms a 'Strong Relative Hazard' for application of rTMS due to the resulting significant seizure threshold lowering potential:

    * Alcohol
    * Barbiturates
    * Benzodiazepines
    * Meprobamate
    * Chloral hydrate

Primary outcomes:
measure: Change in Nocturnal Heart Rate as measured by OURA Ring
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Nocturnal Heart Rate Variability as measured by OURA Ring
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Sleep Latency as measured by OURA Ring
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Sleep Score as measured by OURA Ring
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Total Sleep Time as measured by OURA Ring
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Sleep Efficiency as measured by OURA Ring
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Sleep Quality as measured via Questionnaire
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Recovery as measured via Questionnaire
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Stress as measured via Questionnaire
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Sustained Attention and Reaction Time
timeFrame: Daily from baseline through study completion at 6 weeks
measure: Change in Subjective Sleep Quality measured via Questionnaire
timeFrame: Weekly from baseline through study completion at 6 weeks.
measure: Change in Subjective Attention measured via Questionnaire
timeFrame: Intake (week 1), Mid-point (week 3) and exit (week 6)
measure: Change in Subjective Anxiety measured via Questionnaire
timeFrame: Intake (week 1), Mid-point (week 3) and exit (week 6)
measure: Change in Subjective Depression measured via Hamilton Depression Rating Scale
timeFrame: Intake (week 1), Mid-point (week 3) and exit (week 6)
measure: Change in Subjective Depression measured via Patient Health Questionnaire
timeFrame: Intake (week 1), Mid-point (week 3) and exit (week 6)
measure: Change in Subjective Anxiety measured via Questionnaire
timeFrame: Weekly from baseline through study completion at 6 weeks
measure: Change in Mood as Indicated via Questionnaire
timeFrame: Daily from baseline through study completion at 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Morgantown
country: United States
facility: WVU Rockefeller Neuroscience Institute
state: West Virginia
Study officials:
References: